李吉旭 | AMiner学者主页

全面呈现 [李吉旭] 的学术影响力

深度挖掘高质量成果与权威引用，让优秀看得见

研究兴趣

20222023

论文（8）

专利

基金项目

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

1To Systematically Evaluate the Feasibility and Safety of Rotary Ablation Combined with Cutting Balloon Technique in Treating Moderate and Severe Coronary Artery Calcification Lesions

李吉旭,程红亮, 李恒兵,焦圣东, 梁浩,孙丙新

目的运用Meta分析评价旋磨联合切割球囊治疗冠状动脉中、重度钙化病变的可行性与安全性.方法检索中文(知网、维普、万方、中国生物医学文献服务系统)和英文(Embase、PubMed、Cochrane Library、Web of sci-ence)数据库,搜集旋磨联合切割球囊技术治疗冠状动脉中、重度钙化病变的随机对照实验,时间为建库起至2022年2月15日,采用Revman5.4.1软件进行Meta分析.结果共纳入6项RCTs,共522例患者,Meta分析显示:与对照组相比,观察组患者预处理后即刻获取管腔直径[MD=0.20,95％CI(0.11,0.28),P＜0.00001]和即刻获取管腔横截面积[MD=0.84,95％CI(0.73,0.95),P＜0.00001]明显更高,经皮冠状动脉介入术后支架内最小管腔直径[MD=0.16,95％CI(0.10,0.23),P＜0.00001]和支架内最小管腔横截面积[MD=0.57,95％CI(0.30,0.84),P＜0.0001]明显更高,管腔横截面积残余狭窄[MD=-2.99,95％CI(-5.13,-0.85),P=0.006]明显更低,观察组患者重复血管重建例数显著低于对照组[MD=-0.05,95％CI(-0.09,-0.01),P=0.02],两组患者MACE事件例数无统计学差异[OR=0.75,95％CI(0.26,2.14),P=0.59].结论对于冠状动脉中、重度钙化病变,旋磨联合切割球囊预处理效果优于旋磨联合普通半顺应性球囊,且术后血运重建发生率低,安全可靠.

2023Journal of Clinical Radiology（2023）

引用

AI阅读

2Meta-analysis of the Correlation between Chinese Medical Syndrome Type of Chronic Heart Failure and B-type Natriuretic Peptide

LI Jixu,ZHANG Lin,ZHANG Na,LI Yunqiang,LI Wei

目的:系统评价慢性心力衰竭中医证型与B型利钠肽的相关性.方法:检索中国知网、万方、维普、the Cochrane Library、EMbase、PubMed、Web of Science数据库,收集慢性心力衰竭中医证型与B型利钠肽相关性的文献,检索时限为建库至2022年3月6日,采用RevMan 5.4.1软件进行Meta分析.结果:共纳入9篇文献.Meta分析结果显示,慢性心力衰竭阳虚水泛证B型利钠肽与气虚血瘀证[MD=632.88,95％CI(338.92,926.85),P<0.0001]、气阴两虚证[MD=1261.04,95％CI(739.06,1783.01),P<0.00001]、心肺气虚证[MD=343.87,95％CI(271.08,416.66),P<0.00001]、心肾阳虚证[MD=388.30,95％CI(101.16,856.22),P<0.0001]比较,差异有统计学意义.结论:现有证据表明,B型利钠肽水平偏高可作为诊断慢性心力衰竭阳虚水泛证的参考.

2023Chinese Journal of Integrative Medicine on Cardio/Cerebrovascular Disease（2023）

引用

AI阅读

3Meta-analysis of clinical efficacy of Xuefu Zhuyu Decoction for post-stroke depression

LI Jixu,ZHANG Lin, LI Wei,GUO Yanlin,LU Hainan

Objective To systematically evaluate the clinical efficacy of Xuefu Zhuyu Decoction（XFZYD） for post-stroke depression. Methods The literature related to the XFZYD treatment of post-stroke depression（randomized controlled trials） was retrieved from databases including Chinese National Knowledge Infrastructure（CNKI）, VIP Chinese Science Journals Database（VIP）, WanFang Data, Chinese Biomedical Literature Service System（SinoMed）, Embase, Pubmed, Cochrane Library and Web of Science. The collected literature was published from the establishment date of each database up to July 10, 2022. The quality of the included literature was evaluated with the Manual Cochrane 5.4.1, and RevMan 5.4.1 was used to perform meta-analysis. Results The included 19 articles in the study involved 1,352 patients, with 679 patients in the observation group and 673 patients in the control group. Meta-analysis results showed that the clinical efficiency of the observation group was higher than that of the control group [OR=4.41,95%CI（3.02,6.44）,P＜0.000 01]; After treatment, observation group had lower scores than control group in Hamilton depression scale（HAMD） [MD=-4.98,95%CI（-6.12,-3.83）], NIH stroke scale（NIHSS） [MD=-4.09,95%CI（-4.74,-3.45）], and activity of daily living scale（ADL） [MD=-4.19,95%CI（-8.16,-0.22）], P＜0.000 01; And the incidence of adverse reactions in the observation group was lower than that in the control group [OR=0.07,95%CI（0.02,0.26）,P＜0.000 01]. Conclusion The combined use of XFZYD with conventional western medicine has more satisfactory efficacy than the single use of conventional therapy for post-stroke depression, and can better improve clinical symptoms and patients’ activity of daily living with good safety; However, the relevant findings need further validation due to the quantity and quality of included literature.

2023Shanghai Journal of Traditional Chinese Medicine（2023）

引用

AI阅读

4血府逐瘀汤联合西药治疗经皮冠状动脉介入术术后再发心绞痛Meta分析

李吉旭,孟宪亮,郭延林,李伟,陆海楠

目的:运用Meta分析评价血府逐瘀汤联合常规西药治疗PCI术后再发心绞痛的临床疗效.方法:检索中文(中国知网、维普、万方、中国生物医学文献服务系统)和英文(Embase、Pub Med、Cochrane Library、Web of sci-ence)数据库,收集血府逐瘀汤联合常规西药治疗PCI术后再发心绞痛的随机对照试验,采用Revman 5.4.1和Sta-ta 15.1软件进行Meta分析,对异质性采用敏感性分析,发表偏倚采用漏斗图评价.结果:共纳入13项RCTs,共1419例患者.观察组患者治疗后中医证候有效例数高于对照组[OR=4.27,95％CI(2.32,7.85),P＜0.01],心电图有效例数高于对照组[OR=3.10,95％CI(2.06,4.67),P＜0.01],心绞痛发作频率[MD=-2.09,95％CI(-2.78,-1.41),P＜0.01]和持续时间[MD=-151.20,95％CI(-210.08,-92.33),P＜0.01]均低于对照组,观察组患者治疗后血浆黏度[MD=-0.70,95％CI(-0.75,-0.65),P＜0.01]、红细胞压积[MD=-5.80,95％CI(-6.10,-5.50),P＜0.01]、全血黏度[MD=-0.90,95％CI(-1.08,-0.72),P＜0.01]和纤维蛋白原[MD=-0.70,95％CI(-0.87,-0.53),P＜0.01]均低于对照组.结论:血府逐瘀汤联合常规西药可有效提高PCI术后再发心绞痛患者的临床疗效.

2023

引用

AI阅读

5Systematic Review of the Efficacy of Coated Biodegradable Drug-Eluting Stents in Small Vessel Intervention

LI Jixu,JIAO Shengdong, LI Wei,李允强

目的运用Meta分析评价涂层可生物降解药物洗脱支架(BP-SES)在小血管介入中的疗效.方法检索知网、维普、万方、SinoMed、Embase、PubMed、Cochrane Library、Web of Science数据库,搜集BP-SES治疗小血管病变的随机对照实验,时间为建库起至2022 年8 月15 日,采用Revman 5.4.1 软件进行Meta分析.结果共纳入5项RCTs,共4248 例患者,结果显示:BP-SES在改善大、小血管病变支架内再狭窄[RR =0.77,95%CI(0.31,1.90),P =0.58]、支架内血栓[RR =1.34,95%CI(0.54,3.37),P =0.53]、靶血管血运重建[RR =1.18,95%CI(0.80,1.74),P =0.39]、全因死亡[RR =1.25,95%CI(0.85,1.83),P =0.26]、心因性死亡[RR =1.62,95%CI(0.54,4.86),P =0.39]、非致死性心梗[RR =1.28,95%CI(0.84,1.93),P =0.25]和MACE事件[RR =1.42,95%CI(0.91,2.21),P =0.12]发生率差别不具有统计学意义.结论 BP-SES治疗冠状动脉小血管病变的有效性和安全性与大血管相近,可以在临床上应用.

2023Journal of Clinical Radiology（2023）

引用

AI阅读

6A Meta-Analysis of the Effect of 10Hz-Rtms on Upper Limb Motor Function Rehabilitation in Stroke Patients

李吉旭, 张林, 郭延林, 梁浩

目的:系统评价10Hz高频重复经颅磁刺激对脑卒中患者上肢运动功能康复的疗效.方法:检索知网、万方、维普、中国生物医学文献服务系统、Cochrane Library、Embase、PubMed、Web of Sci-ence数据库,收集10Hz高频重复经颅磁刺激治疗脑卒中患者上肢运动障碍的随机对照试验,采用Re-man5.4.1软件进行Meta分析.结果:共纳入18项RCTs,共1045例患者,与对照组相比,观察组患者的FMA水平明显更高[MD=8.56,95％CI(6.59,10.54),P<0.00001]、MEP潜伏期水平明显更低[MD=-0.35,95％CI(-0.47,-0.23),P<0.00001]、CMCT水平明显更低[MD=-1.06,95％CI(-1.63,-0.49),P=0.00003]、MBI水平明显更高[MD=9.29,95％CI(7.42,11.16),P<0.00001].结论:10Hz高频重复经颅磁刺激可显著改善脑卒中患者的上肢运动功能效果.

2022

引用

AI阅读

7Meta-analysis of Banxia Baizhu Tianma decoction in treating H-type hypertension

LI Jixu,ZHANG Lin,LI Cai,QIN Houwei

目的:系统评价半夏白术天麻汤治疗H型高血压的有效性与安全性.方法:检索中国知网、万方、维普、中国生物医学文献服务系统、Embase、Cochrane Library、Pub Med数据库中半夏白术天麻汤治疗H型高血压的随机对照试验,时间为建库起至2021年11月14日,用Revman 5.4.1软件进行Meta分析,对异质性采用敏感性分析,发表偏倚采用漏斗图评价.结果:共纳入19项随机对照试验,共1449例患者,Meta分析显示:与对照组相比,观察组患者的收缩压明显更低[MD=-10.37,95％CI(-12.62,-8.11),P<0.00001]、舒张压明显更低[MD=-8.72,95％CI(-10.05,-7.38),P<0.00001)]、血同型半胱氨酸水平明显更低[MD=-3.91,95％CI(-4.67,-3.16),P<0.00001],两组患者不良反应比较,差异无统计学意义.结论:半夏白术天麻汤可明显改善H型高血压患者的血压和血同型半胱氨酸水平,且安全性较好.

2022Shaanxi Journal of Traditional Chinese Medicine（2022）

引用

AI阅读

8Meta-analysis of Rotational Atherectomy Combined with Cutting Balloon in the Treatment of Moderate and Severe Coronary Artery Calcification